StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
AVNT

Avient Corporation

AVNT NYSE Plastic Materials, Synth Resins & Nonvulcan Elastomers EDGAR ↗
$40.78
-0.41 -1.00%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$3.74B
Revenue (TTM) ⓘ
$3.33B
Net income (TTM) ⓘ
$170M
EPS (TTM) ⓘ
$1.85
P/E ratio ⓘ
22.0
Dividend yield ⓘ
2.69%
Free cash flow ⓘ
$195M
Cash ⓘ
$426M
Total assets ⓘ
$6.00B
Gross margin ⓘ
31.7%
52-week range ⓘ
$27.48 – $46.64

AI briefing

from the latest 10-K, 10-Q and 8-K events

Avient Corporation is an Ohio-based formulator of specialty engineered materials, composites, performance fibers and color/additive solutions, with 2025 sales of $3.3 billion and about 61% of sales outside the United States.

What they do

Avient does not produce commodity base resins; it sources resins, polymers and additives and formulates them into engineered materials for specific end uses. Products include specialty engineered materials, performance fibers, advanced composites, and color and additive solutions, plus performance-enhancing additives, liquid colorants and silicone colorants. The company operates 98 manufacturing sites across North America, South America, Asia, EMEA and serves end markets including consumer, packaging, defense, healthcare, industrial, transportation, building and construction, telecommunications and energy.

Revenue drivers

  • Specialty engineered materials and composites — Formulated thermoplastic and composite materials sold to processors and assemblers; the 10-Q references a SEM segment and its planned maintenance costs, and the company describes two reportable business segments overall.
  • Color and additive solutions — Liquid colorants, silicone colorants and performance-enhancing additives sold to polymer processors; positioned as a specialized developer and manufacturer rather than a resin producer.
  • Performance fibers — Performance fiber products listed among the company's product lines; no separate revenue figure is disclosed in the excerpts.
  • Growth vectors (defense and healthcare) — Company-identified targeted markets where growth-vector sales are described as outpacing the rest of the company, with defense and healthcare leading in 2025.

Recent performance

Second quarter 2026 sales rose 5.8% to $917.0 million, with 4.3% organic growth and 1.5% favorable foreign exchange, and organic growth in both segments. GAAP EPS was $0.70 versus $0.57 a year earlier, and adjusted EPS was $0.96 versus $0.80, up 20%. Gross margin was 33.5% of sales versus 32.1%, helped by higher sales, productivity and restructuring savings, and the absence of about $3.0 million of prior-year SEM maintenance costs. For the six months ended June 30, 2026, sales were $1,764.4 million versus $1,693.1 million, and net income attributable to Avient common shareholders was $120.5 million versus $32.4 million, aided by the prior-year $71.6 million S/4HANA impairment and $14.7 million of related charges.

Strategy

Avient's stated two-pronged strategy is to build new platforms of scale in high-growth markets and to catalyze the core business. It uses four strategic drivers: portfolio prioritization, amplifying innovation, digital for operational excellence and growth, and leadership, talent and culture. Management says growth-vector sales are outpacing the rest of the company, led by defense and healthcare, with increased internal R&D collaboration and digital pilot projects. Cash generation is directed at growth investment and balance sheet improvement, including debt repayment.

Risks

  • International operations exposure — About 61% of sales are outside the U.S., exposing Avient to tariff and trade restrictions, foreign currency controls, expropriation, tax policy changes and political instability.
  • Raw material and supply chain dependence — Avient does not produce commodity base resins and depends on large chemical producers for inputs, so supply chain disruptions or input cost swings pass through its cost of sales.
  • End-market demand concentration — Results depend on a set of end markets where trends diverge; in the first half of 2026, packaging and building & construction strength had to offset declines in transportation and healthcare.
  • Chemical regulation and compliance — The company cites legislation regulating chemical use and international trade, export control, sanctions and anti-corruption laws as risks inherent in its global operations.

Outlook

Management raised full-year 2026 adjusted EPS guidance to $3.10–$3.25 from $2.93–$3.17, representing 10% to 15% growth, and increased adjusted EBITDA guidance to $575–$603 million. The company expects to repay $100–$150 million of debt during 2026, after $50 million repaid in the second quarter. Management cites year-to-date results and visibility into third quarter demand as support for the higher range, while pointing to a volatile business environment.

Recent SEC filings

40 most recent
Annual, quarterly & current reports